Javed Butler1, Muhammad Shariq Usman2, Muhammad Shahzeb Khan1, Stephen J Greene3, Tim Friede4,5, Muthiah Vaduganathan6, Gerasimos Filippatos7, Andrew J Stewart Coats8,9, Stefan D Anker10. 1. Department of Medicine, University of Mississippi Medical Center, 2500 N. State Street, Jackson, MS, 39216, USA. 2. Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan. 3. Division of Cardiology, Duke University Medical Center, Durham, NC, USA. 4. Department of Medical Statistics, University Medical Center Goettingen, Goettingen, Germany. 5. DZHK (German Center of Cardiovascular Research), partner site Goettingen, Goettingen, Germany. 6. Heart and Vascular Center, Brigham and Women's Hospital, Boston, MA, USA. 7. National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece. 8. Department of Cardiology, IRCCS San Raffaele Pisana, Rome, Italy. 9. University of Warwick, Coventry, UK. 10. Department of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK), partner site Berlin, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, D-13353, Berlin, Germany.
Abstract
AIMS: We sought to conduct a meta-analysis regarding the safety and efficacy of sodium-glucose co-transporter 2 (SGLT2) inhibitors in patients with heart failure (HF). METHODS AND RESULTS: MEDLINE, Scopus, Cochrane CENTRAL, and ClinicalTrials.gov were searched from their inception to November 2020 for placebo-controlled randomized controlled trials of SGLT2 inhibitors. Randomized controlled trials were selected if they reported at least one of the prespecified outcomes in patients with HF. Hazard ratios (HRs) or risk ratios and their corresponding 95% confidence intervals were pooled using a random-effects model. A total of seven trials including 16 820 HF patients (N = 8884 in the SGLT2 inhibitor arms; N = 7936 in the placebo arms) were included. In the overall HF cohort, SGLT2 inhibitors compared with placebo significantly reduced the risk of the composite endpoint of first HF hospitalization or cardiovascular death [HR: 0.77 (0.72-0.83); P < 0.001; I2 = 0%], time to first HF hospitalization [HR: 0.71 (0.64-0.78); P < 0.001; I2 = 0], cardiovascular mortality [HR: 0.87 (0.79-0.96); P = 0.005; I2 = 0%], and all-cause mortality [HR: 0.89 (0.82-0.96); P = 0.004; I2 = 0%]. Results remained consistent across HF-specific trials and according to diabetes mellitus status. A trend towards benefit was observed in patients with HF with preserved ejection fraction for the composite of HF hospitalization and cardiovascular death [HR: 0.80 (0.63-1.00); P = 0.05; I2 = 29%]. No increased risk of hypovolaemia, hyperkalaemia, and hypotension was seen with SGLT2 inhibitors compared with placebo. CONCLUSIONS: SGLT2 inhibitors significantly improve cardiovascular outcomes including cardiovascular and all-cause mortality in patients with HF without an increased risk of serious adverse events. A trend towards benefit was observed in patients with HF with preserved ejection fraction.
AIMS: We sought to conduct a meta-analysis regarding the safety and efficacy of sodium-glucose co-transporter 2 (SGLT2) inhibitors in patients with heart failure (HF). METHODS AND RESULTS: MEDLINE, Scopus, Cochrane CENTRAL, and ClinicalTrials.gov were searched from their inception to November 2020 for placebo-controlled randomized controlled trials of SGLT2 inhibitors. Randomized controlled trials were selected if they reported at least one of the prespecified outcomes in patients with HF. Hazard ratios (HRs) or risk ratios and their corresponding 95% confidence intervals were pooled using a random-effects model. A total of seven trials including 16 820 HF patients (N = 8884 in the SGLT2 inhibitor arms; N = 7936 in the placebo arms) were included. In the overall HF cohort, SGLT2 inhibitors compared with placebo significantly reduced the risk of the composite endpoint of first HF hospitalization or cardiovascular death [HR: 0.77 (0.72-0.83); P < 0.001; I2 = 0%], time to first HF hospitalization [HR: 0.71 (0.64-0.78); P < 0.001; I2 = 0], cardiovascular mortality [HR: 0.87 (0.79-0.96); P = 0.005; I2 = 0%], and all-cause mortality [HR: 0.89 (0.82-0.96); P = 0.004; I2 = 0%]. Results remained consistent across HF-specific trials and according to diabetes mellitus status. A trend towards benefit was observed in patients with HF with preserved ejection fraction for the composite of HF hospitalization and cardiovascular death [HR: 0.80 (0.63-1.00); P = 0.05; I2 = 29%]. No increased risk of hypovolaemia, hyperkalaemia, and hypotension was seen with SGLT2 inhibitors compared with placebo. CONCLUSIONS: SGLT2 inhibitors significantly improve cardiovascular outcomes including cardiovascular and all-cause mortality in patients with HF without an increased risk of serious adverse events. A trend towards benefit was observed in patients with HF with preserved ejection fraction.
Authors: Thomas A Zelniker; Stephen D Wiviott; Itamar Raz; Kyungah Im; Erica L Goodrich; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Remo H M Furtado; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Marc S Sabatine Journal: Lancet Date: 2018-11-10 Impact factor: 79.321
Authors: Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi Journal: N Engl J Med Date: 2015-09-17 Impact factor: 91.245
Authors: Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews Journal: N Engl J Med Date: 2017-06-12 Impact factor: 91.245
Authors: Deepak L Bhatt; Michael Szarek; Bertram Pitt; Christopher P Cannon; Lawrence A Leiter; Darren K McGuire; Julia B Lewis; Matthew C Riddle; Silvio E Inzucchi; Mikhail N Kosiborod; David Z I Cherney; Jamie P Dwyer; Benjamin M Scirica; Clifford J Bailey; Rafael Díaz; Kausik K Ray; Jacob A Udell; Renato D Lopes; Pablo Lapuerta; P Gabriel Steg Journal: N Engl J Med Date: 2020-11-16 Impact factor: 91.245
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: BMJ Date: 2009-07-21
Authors: Faiez Zannad; João Pedro Ferreira; Stuart J Pocock; Stefan D Anker; Javed Butler; Gerasimos Filippatos; Martina Brueckmann; Anne Pernille Ofstad; Egon Pfarr; Waheed Jamal; Milton Packer Journal: Lancet Date: 2020-08-30 Impact factor: 79.321
Authors: Mark C Petrie; Subodh Verma; Kieran F Docherty; Silvio E Inzucchi; Inder Anand; Jan Belohlávek; Michael Böhm; Chern-En Chiang; Vijay K Chopra; Rudolf A de Boer; Akshay S Desai; Mirta Diez; Jaroslaw Drozdz; Andre Dukát; Junbo Ge; Jonathan Howlett; Tzvetana Katova; Masafumi Kitakaze; Charlotta E A Ljungman; Béla Merkely; Jose C Nicolau; Eileen O'Meara; Pham Nguyen Vinh; Morten Schou; Sergey Tereshchenko; Lars Køber; Mikhail N Kosiborod; Anna Maria Langkilde; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Mikaela Sjöstrand; Scott D Solomon; Per Johanson; Peter J Greasley; David Boulton; Olof Bengtsson; Pardeep S Jhund; John J V McMurray Journal: JAMA Date: 2020-04-14 Impact factor: 56.272
Authors: Karin Rådholm; Gemma Figtree; Vlado Perkovic; Scott D Solomon; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Terrance D Barrett; Wayne Shaw; Mehul Desai; David R Matthews; Bruce Neal Journal: Circulation Date: 2018-07-31 Impact factor: 29.690
Authors: Marcus Säemann; Daniel Cejka; Sabine Schmaldienst; Alexander R Rosenkranz; Gert Mayer Journal: Wien Klin Wochenschr Date: 2022-10-17 Impact factor: 2.275
Authors: Tobias Täger; Lutz Frankenstein; Dan Atar; Stefan Agewall; Norbert Frey; Morten Grundtvig; Andrew L Clark; John G F Cleland; Hanna Fröhlich Journal: Clin Res Cardiol Date: 2021-09-08 Impact factor: 5.460
Authors: Muhammad Shariq Usman; Muhammad Shahzeb Khan; Gregg C Fonarow; Stephen J Greene; Tim Friede; Muthiah Vaduganathan; Gerasimos Filippatos; Andrew J Stewart Coats; Stefan D Anker; Javed Butler Journal: ESC Heart Fail Date: 2022-01-13